ResMed

What ResMed does

ResMed Inc. is a San Diego-headquartered, publicly traded medical device and digital health company (NYSE and ASX: RMD) founded in 1989, operating in 140+ countries with 5,001–10,000 employees. The company develops cloud-connected PAP therapy devices — AirSense 10 (auto-adjusting APAP), AirCurve 10 and AirCurve 11 (bilevel), AirMini (travel CPAP), AirStart 10 (entry-level CPAP) — alongside the Astral, Stellar, and Lumis ventilator families for COPD, neuromuscular disease, and chronic respiratory insufficiency. Its connected mask portfolio (AirFit F20/N20/P10/AirTouch) drives a recurring consumables resupply business. Core proprietary technology includes the AutoSet auto-adjusting algorithm, Expiratory Pressure Relief (EPR), intelligent Volume-Assured Pressure Support (iVAPS), Easy-Breathe waveform, and Climate Control humidification, plus FDA-cleared AI features (Smart Comfort device) and the DAWN generative AI virtual assistant.

ResMed operates a platform-plus-modules business model anchored by the myAir patient coaching app, AirView cloud-based remote patient monitoring, ReSupply and U-Sleep workflow automation, ResScan titration software, and home sleep testing diagnostics (NightOwl, ApneaLink Air). Acquired assets extend the stack: Propeller Health (respiratory inhaler sensors), Brightree/MatrixCare/CitusHealth (residential care EHR and patient communication), Somnoware (sleep diagnostic management), Somnio (reimbursed digital insomnia therapy via Mementor), VirtuOx (sleep/respiratory/cardiac diagnostic testing facility), and Nidra TOMAC Therapy (FDA De Novo-classified Restless Legs Syndrome neuromodulation via Noctrix Health, $340M acquisition closed June 1, 2026). The Oura Ring partnership (May 2026) and Zepbound complementary positioning route consumer wearable users and GLP-1-prescribed OSA patients into the clinical pathway.

Revenue is generated through hardware sales (CPAP/APAP/bilevel machines, masks), razor-and-blades recurring consumables resupply, SaaS subscriptions (AirView, Brightree, MatrixCare, CitusHealth, Propeller Health), and virtual/professional services (VirtuOx, sleep.resmed.com). Customers include OSA patients (estimated 1 billion adults aged 30–69 globally with OSA, 80% undiagnosed), chronic respiratory patients, healthcare professionals, Home Medical Equipment providers, sleep labs, and residential care operators. Distribution spans a direct-to-consumer online storefront, authorized HME/channel resellers, regional distributor offices (notably São Paulo for LATAM), direct enterprise sales to hospitals and IDNs, and emerging virtual care channels. Q3 FY2026 revenue was $1,431.4 million (+11% YoY), operating margin 36.7%, non-GAAP gross margin 62.8% (+290 bps), with FY25 gross revenue of approximately $5.15 billion and a market capitalization near $29.7 billion.

Name

ResMed

Legal name

ResMed Corp.

Website

https://resmed.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

ResMed develops cloud-connected CPAP, bilevel, and ventilation devices, masks, and digital health software (AirView, myAir, Brightree) for obstructive sleep apnea and chronic respiratory patients, serving 140+ countries with hardware, recurring consumables, and SaaS revenue streams.

Ownership category

akta.pro rank

Product category

Sleep Apnea and Respiratory Care Medical Devices

NAICS

Home Health Equipment Rental (532283), Ventilation, Heating, Air-Conditioning, and Commercial Refrigeration Equipment Manufacturing (3334)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Home Health Care Services (8082)

akta.pro primary industry

Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV) (HLAHAGAA)

akta.pro secondary industries

Home Respiratory & Sleep Therapy Providers (DME-Integrated) (HLAFAEAF), Pulmonology & Sleep Medicine Telemedicine Platforms (HLALAGAF), Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB)

Keywords

• Sleep apnea therapy
• Connected medical devices
• Respiratory care solutions
• Digital health platform
• Ventilation equipment

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Sleep apnea devices and masks hardware sales: Q3 FY2026 device sales grew 6% and masks grew 12% globally. Includes one-time hardware sale of CPAP/APAP/bilevel machines (AirSense, AirCurve, AirMini, Astral, Stellar) and initial mask purchases. Q3 FY2026 total revenue of $1,431.4 million, up 11% year-over-year.
2. Consumables and resupply (razor-and-blades): Recurring revenue from mask replacement cushions, headgear, filters, tubing, and water tubs driven by ResMed's resupply programs (ReSupply) and patient compliance; 12% masks growth in Q3 FY2026 indicates strong consumables momentum.
3. Digital health SaaS (AirView, myAir, Propeller Health): Software-as-a-service and connected health platform revenue from AirView (provider remote monitoring), myAir (patient engagement), Propeller Health (respiratory inhaler adherence), and Residential Care Software suite (Brightree, MatrixCare, CitusHealth) for residential care providers.
4. Virtual care and clinical services: Virtual care offerings via sleep.resmed.com and the VirtuOx independent diagnostic testing facility (acquired) for sleep, respiratory, and cardiac diagnostic testing services.
5. Digital therapeutics (Somnio insomnia app): Reimbursed digital insomnia therapy via Somnio app acquired through Mementor in Germany.
6. Patient funding (dividends and buybacks): Capital return to shareholders: $262 million returned to shareholders in Q3 FY2026 through share repurchases and a $0.60 quarterly dividend (payable June 18, 2026).

Pricing tiers

Go-to-market motion1 record

Distribution channels7 records

Marketing channels10 records

Core offering

ResMed designs, manufactures, and sells cloud-connected medical devices (CPAP, APAP, bilevel, and ventilators) along with masks and consumables for obstructive sleep apnea, COPD, and chronic respiratory care. The hardware is paired with a connected digital health stack — AirView remote monitoring, myAir patient coaching, ReSupply/U-Sleep business automation, and Propeller Health inhaler sensors — and complemented by residential care software (Brightree, MatrixCare, CitusHealth) sold to home health, hospice, and post-acute providers.

Product overview

ResMed operates a platform-plus-modules architecture centered on connected sleep and respiratory care. The core therapy platform comprises cloud-connected PAP and ventilation hardware — AirSense 10 (AutoSet CPAP/APAP), AirCurve 10 and AirCurve 11 (bilevel), AirMini (travel CPAP), AirStart 10 (entry-level CPAP), and the Astral, Stellar, and Lumis ventilator families — together with the AirTouch F20, AirFit F20 / F30 / N20 / N20 Classic / N30i, and AirFit P10 / P30i mask portfolio. The hardware feeds the myAir patient app, AirView cloud platform, ReSupply, U-Sleep, ResScan, and EasyCare Tx 2 software layer, with the FDA-cleared Smart Comfort device and DAWN generative AI assistant embedded across the experience. ResMed's diagnostics module — NightOwl, ApneaLink Air, and ApneaLink Plus — sits alongside home sleep testing tools. Acquired and partner assets extend the platform: Propeller Health (respiratory inhaler sensors), Brightree, MatrixCare, CitusHealth, and Somnoware (residential care and diagnostic workflows); Nidra® TOMAC Therapy for Restless Legs Syndrome from the Noctrix Health acquisition; Somnio from the Mementor acquisition (digital insomnia therapy); and VirtuOx for virtual sleep, respiratory, and cardiac diagnostics. The Oura Ring partnership adds a consumer wearable data feed into ResMed's clinical care pathway.

Differentiator

Problem solved

Functional benefit

Brands

• AirSense: CPAP/APAP sleep apnea device product line.
• AirCurve
• AirMini
• Astral
• Stellar
• Lumis
• myAir
• AirView
• AirTouch
• ApneaLink Air
• NightOwl
• ResScan
• Nidra (TOMAC Therapy)

Products and services

• AirSense 10 Flagship auto-adjusting CPAP (APAP) device with HumidAir heated humidifier, wireless connectivity, the AutoSet algorithm, Expiratory Pressure Relief (EPR), and SmartStart; therapy data syncs to myAir and AirView for patient coaching and clinician remote monitoring.
• AirCurve 10 Bilevel positive airway pressure (BiPAP) device for patients requiring higher pressure support or those who cannot tolerate CPAP, featuring integrated humidifier, wireless connectivity, and adaptive algorithms.
• AirCurve 11 Bilevel Devices Newer-generation bilevel PAP device with dual pressure settings, integrated humidification, and wireless connectivity for remote monitoring of sleep apnea, COPD, and respiratory disorders.
• AirMini ResMed's smallest portable travel CPAP, featuring ActiveAir technology, waterless HumidX/HumidX Plus humidification, Bluetooth pairing with the AirMini app, and therapy performance equivalent to AirSense 10.
• AirStart 10 Entry-level auto-adjusting CPAP device in the Air 10 family with simplified features, SD-card-based data storage, and a simplified APAP algorithm compared with AirSense 10 AutoSet.
• Astral ResMed's high-acuity life-support ventilator with iVAPS mode, double-limb circuit capability, and data connectivity via AirView; supports invasive and non-invasive ventilation across hospital and home settings for chronic respiratory insufficiency.
• Stellar ResMed's adult and pediatric non-invasive/invasive ventilator for hospital and home use, supporting pressure and volume modes for chronic respiratory insufficiency.
• Lumis ResMed's non-invasive ventilator series for adult and pediatric patients with respiratory insufficiency, including iVAPS and high-flow oxygen therapy support, with cloud connectivity to AirView.
• AirTouch F20 Full face CPAP mask featuring an UltraSoft memory foam cushion for a softer seal, compatible with AirSense/AirCurve 10, AirMini, and AirStart 10 devices.
• AirFit F20 / F30 / N20 / N20 Classic / N30i / P10 / P30i mask family ResMed's broader CPAP mask portfolio including the silicone-cushion AirFit F20 full face, compact AirFit F30 under-nose full face, InfinitySeal AirFit N20 / N20 Classic nasal, top-of-head tube AirFit N30i nasal cradle, AirFit P10 minimalist nasal pillow, and AirFit P30i top-of-head tube nasal pillow masks.
• NightOwl Wireless, disposable fingertip home sleep apnea diagnostic device for multi-night, at-home diagnosis of obstructive sleep apnea, launched April 2025.
• ApneaLink Air Type III home sleep testing recorder used for screening and diagnosis of obstructive sleep apnea, integrated with AirView for ApneaLink Air.
• myAir Patient coaching app for AirSense 10, AirCurve 10, Lumis, and AirMini users that delivers daily sleep scores, coaching tips, cleaning reminders, mask fit and supplies notifications, and adherence tracking with a Streaks feature for consecutive-night tracking.
• AirMini app Companion smartphone app for the AirMini travel CPAP that pairs over Bluetooth to deliver therapy scores, comfort settings, mask fit, and data sync to AirView.
• AirView ResMed's secure cloud-based patient management platform for sleep and ventilation therapy, providing remote monitoring, Action Groups, Remote Assist, and integration with EHR workflows for HCPs and HME providers.
• ReSupply Automated resupply solution for HME providers that reorders CPAP masks, cushions, headgear, and filters for patients based on replacement guidelines.
• U-Sleep Compliance management solution that uses automated outreach to engage non-compliant CPAP patients and helps HME providers meet Medicare and payer compliance thresholds.
• ResScan Desktop therapy-management software used by clinicians to download, review, and report detailed therapy data from ResMed CPAP, bilevel, and ventilation devices.
• EasyCare Tx 2 and S9 VPAP Tx Lab System EasyCare Tx 2 titration software works with the S9 VPAP Tx Lab System to remotely control therapy devices during in-lab polysomnography-guided CPAP/BiPAP titration studies in sleep labs.
• Propeller Health Respiratory medication adherence platform that attaches sensors to inhalers (asthma and COPD) and pairs them with a smartphone app to track usage, location, and triggers for clinician review.
• Brightree EHR and business management platform for home medical equipment (HME), home health, hospice, and pharmacy providers.
• MatrixCare EHR platform purpose-built for skilled nursing, senior living, and long-term care providers, supporting clinical, financial, and operational workflows.
• CitusHealth Patient and family engagement platform enabling secure messaging, document exchange, and care-team collaboration for home-based and post-acute care.
• Nidra Tonic Motor Activation (TOMAC) Therapy FDA De Novo-classified, non-invasive wearable neuromodulation therapy for moderate-to-severe Restless Legs Syndrome in adults who have not found sufficient relief with drug therapy; acquired via the $340M Noctrix Health deal closing June 1, 2026.
• Somnio Digital insomnia therapy app acquired with Mementor in August 2022; approved for reimbursement in Germany and shown in clinical trials to deliver sustained sleep improvements.
• VirtuOx Independent diagnostic testing facility for sleep, respiratory, and cardiac conditions, acquired May 2025; operates as a ResMed subsidiary and extends virtual/home-based diagnostic services.
• Smart Comfort AI-enabled therapy feature FDA-cleared AI-enabled device/feature highlighted by ResMed CMO Carlos Nunez as part of ResMed's AI-enabled product set, used to personalize CPAP therapy comfort and adherence.
• DAWN generative AI assistant ResMed's 24/7 generative AI virtual assistant for sleep disorders that supports sleep health education, navigation, and patient interaction on the ResMed website.

Segments8 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability10 records

Feature11 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• Oura (ŌURA)flagshipStrategic or Co-development Partner · 19 May 2026ResMed and Oura announced a partnership on May 19, 2026 (live since April 28) to connect Oura Ring Gen3 and Ring 4 users with elevated nighttime breathing disturbances to ResMed's sleep health resources, including sleep assessments, educational materials, and virtual or in-person healthcare provider options. The integration targets the estimated 80% of Americans with undiagnosed OSA and 80 million affected, with initial rollout to US members with active Oura Memberships. The partnership tests ResMed's shift from a hardware-focused model to a more integrated digital offering against competitors like Philips and Fisher & Paykel.
• Noctrix Health, Inc.flagshipStrategic or Co-development Partner · 30 April 2026ResMed completed its $340 million acquisition of Noctrix Health on June 1, 2026, with the deal announced April 30, 2026. Noctrix becomes a wholly owned subsidiary within the ResMed group, adding Nidra® Tonic Motor Activation (TOMAC) Therapy — an FDA De Novo classified non-pharmacologic treatment for moderate-to-severe Restless Legs Syndrome backed by 10 peer-reviewed publications and included in AASM clinical guidelines. ResMed plans to integrate Noctrix's technology into its connected devices and digital health portfolio to expand patient access and advance its 2030 strategy. CEO Mick Farrell noted RLS has meaningful overlap with ResMed's core OSA market and that Noctrix is growing faster with higher gross margins than ResMed itself.
• Eli Lilly (Zepbound/tirzepatide)coreGTM or Marketing Partner · 17 April 2026ResMed has publicly positioned CPAP therapy as complementary to Eli Lilly's GLP-1 obesity drug Zepbound (tirzepatide), which the FDA approved on December 20, 2024 for moderate-to-severe OSA in adults with obesity. ResMed's CMO Carlos Nunez welcomed the approval, citing ResMed's IQVIA real-world analysis showing GLP-1 + OSA patients are 10.8 percentage points more likely to initiate CPAP therapy and have higher resupply rates at 1 and 2 years.
• VirtuOxcoreStrategic or Co-development Partner · 1 May 2025ResMed acquired VirtuOx, an independent diagnostic testing facility for sleep, respiratory, and cardiac conditions, to enhance its digital health offerings and expand access to diagnosis. VirtuOx operates as a subsidiary within ResMed and supports ResMed's strategy to improve healthcare delivery through virtual services and digital innovation. The deal was referenced in April 2026 industry coverage of the respiratory diagnostics market.
• Mementor (Somnio app)coreStrategic or Co-development Partner · 2 August 2022ResMed acquired Mementor and its digital insomnia therapy app Somnio in Germany in 2022 to strengthen its sleep portfolio. The deal aims to expand adoption of Somnio, which is approved for reimbursement and has shown sustained sleep improvements through clinical trials.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Philips (Respironics): Philips Respironics is ResMed's largest direct competitor in CPAP/APAP/bilevel devices and masks. The 2021 Philips CPAP recall reshaped the competitive landscape in ResMed's favor, but Philips' recovery trajectory is a key variable for ResMed's device market share and pricing.
• Fisher & Paykel Healthcare: New Zealand-based F&P Healthcare is ResMed's primary competitor in hospital and home respiratory care, with overlapping CPAP, mask, and humidification portfolios. F&P's Airvo high-flow nasal cannula and growing mask business are direct competitive threats to ResMed's installed base.
• Invacare Holdings: Invacare is a smaller direct competitor in home medical equipment including CPAP and respiratory products, primarily serving the HME channel. While smaller in scale than ResMed, Invacare competes for the same HME resellers and durable medical equipment reimbursement dollars.
• Drive DeVilbiss Healthcare: Drive DeVilbiss is a direct competitor in CPAP/APAP devices, masks, and home respiratory care distributed through the same HME channel as ResMed. Comparable product breadth in entry-level and mid-tier CPAP segments.

Emerging players

• Inspire Medical Systems: Inspire markets an implantable hypoglossal nerve stimulation system for moderate-to-severe OSA patients who cannot tolerate CPAP. Inspire represents an alternative-treatment competitor that could cap ResMed's CPAP TAM if payer coverage expands for neurostimulation as second-line therapy.
• Oura: Oura is a consumer smart ring maker that has partnered with ResMed to route users with elevated nighttime breathing disturbances into ResMed's clinical pathway. It is both a partner and a potential disruptor as consumer-grade sleep apnea screening features proliferate on wearables.

Broad incumbents

• Baxter International: Baxter is a diversified medical device and pharma incumbent with overlapping hospital respiratory and home care product lines, plus potential software adjacencies. CFO Aaron Bloomer's prior senior role at Baxter highlights its relevance as ResMed's new CFO's former employer and broader industry peer.
• Medtronic: Medtronic is a global medtech incumbent with adjacent respiratory, ventilation, and remote patient monitoring capabilities that overlap with ResMed's Astral/Stellar/Lumis ventilator line and connected care platforms, though Medtronic does not specialize in sleep apnea CPAP.
• GE HealthCare: GE HealthCare provides hospital-grade patient monitoring, anesthesia, and respiratory solutions that overlap with ResMed's hospital ventilation portfolio. As a broader diagnostic and monitoring incumbent, GE represents competitive risk in hospital-channel ventilator sales.
• 3M Health Care: 3M is a diversified health care incumbent with adjacent patient monitoring and respiratory product lines. New ResMed CFO Aaron Bloomer previously held a senior role at 3M, indicating industry familiarity; 3M is relevant as a broad incumbent operating in adjacent connected care and respiratory markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/resmed
• Xx.com/resmed
• Facebookfacebook.com/resmed

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries8 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A30 records

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ResMed